Ocugen, Inc.
OCGNHealthcare|Biotechnology|US
$0.93
+0.11 (+13.29%)
Cash / Share
$0.25
Clinical Trials (13)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07770828 Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD | Dry Age-related Macular Degeneration | P3 | Recruiting | 237 | RCT, Single-blind | OCU410 |
| NCT06388200 A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | Retinitis Pigmentosa | P3 | Active | 140 | RCT, Single-blind | — |
| NCT05956626 A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease | Stargardt Disease | P2P3 | Active | 51 | RCT, Single-blind | OCU410ST |
| NCT06018558 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy | Geographic Atrophy | P1P2 | Active | 60 | RCT, Single-blind | — |
| NCT05203939 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis | Retinitis Pigmentosa, Leber Congenital Amaurosis | P1P2 | Active | 22 | Open-label | OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing |
| NCT05802329 Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) | Center Involved Diabetic Macular Edema, Diabetic Macular Edema | P1 | Recruiting | 24 | Open-label | OCU200 |
| NCT03785340 Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED) | Dry Eye | P3 | Completed | 252 | RCT, Double-blind | Brimonidine Tartrate, Placebos |
| NCT05258669 Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults | COVID-19 | P2P3 | Unknown | 400 | RCT, Double-blind | BBV152 |
| NCT03591874 Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease | Graft Versus Host Disease, Ocular Surface Disease | P3 | Terminated | 59 | RCT, Double-blind | Brimonidine Tartrate, Placebos |
| NCT03418727 Dry Eye Disease Study With Brimonidine | Dry Eye | P2 | Completed | 84 | RCT, Double-blind | Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop |
| NCT02975557 Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD) | Dry Eye, Ocular Graft vs Host Disease | P1P2 | Terminated | 15 | RCT, Double-blind | Brimonidine 0.15%, Brimonidine 0.075%, Placebo |
| NCT05541289 Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older | COVID-19 | NO_LONGER_AVAILABLE | — | — | BBV152 | |
| NCT06574997 Expanded Access Program for RP in Adults | Retinitis Pigmentosa | NO_LONGER_AVAILABLE | — | — | OCU400 |